Investors Target GeneDx in Securities Fraud Class Action

The litigation centers on claims that GeneDx violated the Securities Exchange Act of 1934 by issuing false or misleading statements. According to the complaint, these misrepresentations became apparent on May 4, 2026, when the company released its first-quarter financial results. During that announcement, GeneDx reported a decline in adjusted gross margins and reduced its earnings projections. Furthermore, the company disclosed a $31.3 million impairment charge tied to its Fabric Genomics division, triggering a market reaction that caused financial harm to shareholders.

The Schall Law Firm, led by Brian Schall, is currently organizing the class action and invites affected investors to reach out before the August 3, 2026, deadline. While the class has not yet been formally certified, shareholders who suffered losses may contact the Los Angeles-based firm to discuss their legal options at no cost. Those who choose not to participate remain absent class members and are not represented by counsel in the ongoing proceedings.